Misonix turns to a digital platform to educate, inform and sell its Bonescalpel.
The Misonix BoneScalpel has seen favourable reviews in new clinical paper accepted for publication by “Neurosurgery,”. In the study the device was used to perform safe, tissue-selective bone dissection that encourages en-bloc bone removal and refined osteotomies while sparing elastic soft tissue structures.
The Misonix® BoneScalpel Ultrasonic Bone Cutter has cropped up in a clinical paper, so why wouldn’t the manufacturer point us at the comments, especially when they say the device offers a good solution for head and neck surgeons when harvesting bone.
Misonix says it is acting in a manner consistent with its business strategy by electing to sell its products under its own label via its own proprietary sales organization. With its now defunct distribution agreement less than 2 years old, Aesculap might be a little aggrieved.
Misonix, Inc. designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery and other specialties. The company has been cited for its BoneScalpel™ which a panel of 5 Spine Experts says is the year’s most exciting technology for spinal surgery.
Misonix, Inc. has entered into a new, three year, exclusive distribution agreement with Ekrior Lda, a Division of Avanco Sistemas Medicos, for the distribution of the SonaStar Ultrasonic Surgical Aspirator, the BoneScalpel Ultrasonic Bone Cutter, and the SonicOne® Ultrasonic Wound Debrider.
Misonix, Inc. has entered into a new, three year, exclusive distribution agreement with Sophysa Benelux, based in Braine l’Alleud, Belgium, for the distribution of the SonaStar Ultrasonic Surgical Aspirator and the BoneScalpel Ultrasonic Bone Cutter.
Misonix, Inc., a developer of minimally invasive ultrasonic medical device technology, has entered into a new, two year, sales agency agreement with privately-held Advanced Oncology Systems.
Two new articles support the notion that the ultrasonic BoneScalpel delivers effective, efficient spinal decompression
Call it trumpet blowing, but who can blame Misonix for pointing us at a new study when that study shows using its technology significantly reduces blood loss.
PuriCore’s UK endoscopy and laboratory business decreased 13%, while Vashe Wound Therapy sales grew 51% increase for the three quarters over the same period in 2010.